May 19, 2025 11:33 AM EDT
People
R&D
Cell/Gene Tx

Prime Med­i­cine side­lines on­ly clin­i­cal pro­gram, re­places CEO and lays off some staff

Lei Lei Wu

News Reporter

In gene edit­ing, sci­en­tif­ic mile­stones and promis­ing ear­ly da­ta do not al­ways mean a pro­gram is valu­able.

Prime Med­i­cine an­nounced Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Re­gen­eron plans to buy 23andMe for $256M

David Liu, Sam Stern­berg un­veil new way to in­sert big genes in hu­man cells

Ex­clu­sive: Cell­Cen­tric col­lects $120M to treat mul­ti­ple myelo­ma with a cap­sule

In­tel­li­a's CRISPR ther­a­py like­ly caus­es 'per­ma­nen­t' gene knock­down in AT­TR amy­loi­do­sis

Ap­n­imed posts first set of Phase 3 sleep ap­nea re­sults, aims for ap­proval fil­ing in 2026

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times